FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cudkowicz Merit Ester				2. Issuer Name and Ticker or Trading Symbol Praxis Precision Medicines, Inc. [PRAX]							(Ch	telationship eck all appli Directo	cable)	g Perso	on(s) to Iss			
(Last)	(Fi	rst)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/05/2024									(give title		Other (s below)	pecify		
C/O PRAXIS PRECISION MEDICINES, INC. 99 HIGH STREET, 30TH FLOOR				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person						
(Street) BOSTON MA 02110				D	Dula 40h5 4(a) Transaction Indication								Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - Noı	n-Deriv	vative	Se	curitie	s Ac	quired,	Dis	osed o	of, or Be	neficial	ly Owned	i			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Transaction Disposed Of Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Benefici	es ally Following	Form: (D) or	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership		
				Code				v	Amount	(A) o (D)	r Price	Transac	ransaction(s) Instr. 3 and 4)			(Instr. 4)		
		Т	able II -									, or Ben ble secu		Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transactio Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$44.25	06/05/2024			A		8,566		(1)	0	6/05/2034	Common Stock	8,566	\$0	8,566		D	

Explanation of Responses:

1. The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 5, 2024.

Remarks:

/s/ Alex Nemiroff, as Attorney-

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.